Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways

Japanese Journal of Cancer Research

Volumn 90, Issue 12, 1999, Pages 1373-1379

  Minagawa, Yukihisa ^a   Kigawa, Junzo ^a   Itamochi, Hiroaki ^a   Kanamori, Yasunohu ^a   Shimada, Muneaki ^a   Takahashi, Masakuni ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cisplatin; Drug resistance; HeLa cells; p53

Indexed keywords

CISPLATIN; DNA FRAGMENT; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; PACLITAXEL; PROTEIN BAX; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; MESSENGER RNA SYNTHESIS; PHENOTYPE; PRIORITY JOURNAL;

EID: 0033386145     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00722.x     Document Type: Article

References (39)

1. Dive, C. and Hickman, J. A. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer, 64, 192-196 (1991).
2. Sen, S. and D'Incalci, M. Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett., 307, 122-127 (1992).
3. Barry, M. A., Behnke, C. A. and Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol., 40, 2353-2362 (1990).
4. Sorenson, C. M., Barry, M. A. and Eastman, A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst., 82, 749-755 (1990).
5. Lane, D. P. Cancer. p53, guardian of the genome. Nature, 358, 15-16 (1992).
6. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311 (1991).
7. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V. and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89, 7491-7495 (1992).
8. Anthoney, D. A., McIlwrath, A. J., Gallagher, W. M., Edlin, A. R. and Brown, R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res., 56, 1374-1381 (1996).
9. Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini. C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C. and Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res., 56, 556-562 (1996).
10. Gallagher, W. M., Cairney, M., Schott, B., Roninson. I. B. and Brown, R. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene, 14, 185-193 (1997).
11. De Feudis, P., Debernardis, D., Beccaglia, P., Valenti, M., Graniela Sire, E., Arzani, D., Stanzione, S., Parodi, S., D'Incalci, M., Russo, P. and Broggini, M. DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br. J. Cancer, 76, 474-479 (1997).
12. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen-Schaub, L. B. and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54, 2287-2291 (1994).
13. Fan, S., Smith, M. L., Rivet, D. J., II, Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., Jr. and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55, 1649-1654 (1995).
14. Hawkins, D. S., Demers, G. W. and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56, 892-898 (1996).
15. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr. and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57, 4285-4300 (1997).
16. Burger, H., Nooter, K., Boersma, A. W., Kortland, C. J. and Stoter, G. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumor cell lines. Int. J. Cancer, 73, 592-599 (1997).
17. Kanamori, Y., Kigawa, J., Minagawa, Y., Irie, T., Oishi, T., Shimada, M., Takahashi, M., Nakamura, T., Sato, K. and Terakawa, N. A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cisdiamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Eur. J. Cancer, 34, 1802-1806 (1998).
18. Matlashewski, G., Banks, L., Pim, D. and Crawford, L. Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur. J. Biochem., 154, 665-672 (1986).
19. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63, 1129-1136 (1990).
20. Schiff, P. B. and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77, 1561-1565 (1980).
21. Kelland, L. R. and Abel, G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol., 30, 444-450 (1992).
22. Wu, G. S. and El-Diery, W. S. p53 and chemosensitivity. Nat. Med., 2, 255-256 (1996).
23. Debernardis, D., Sire, E. G., De Feudis, P., Vikhanskaya, F., Valenti, M., Russo, P., Parodi, S., D'Incalci, M. and Broggini, M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res., 57, 870-874 (1997).
24. Graniela Sire, E. A., Vikhanskaya, F. and Broggini, M. Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Ann. Oncol., 6, 589-593 (1995).
25. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y., Foster, S. A., Demers, G. W. and Galloway, D. A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med., 2. 72-79 (1996).
26. Vikhanskaya, F., Vignati, S., Beccaglia, P., Ottoboni, C., Russo, P., D'Incalci, M. and Broggini, M. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp. Cell Res., 241, 96-101 (1998).
27. Woods, C. M., Zhu, J., McQueney, P. A., Bollag, D. and Lazarides, E. Taxol-induced mitotic black triggers rapid onset of a p53-independent apoptotic pathway. Mol. Med., 1, 506-526 (1995).
28. Banerjee, S., Fallis, A. G. and Brown, D. L. Differential effects of taxol on two human cancer cell lines. Oncol. Res., 9, 237-248 (1997).
29. Torres, K. and Horwitz, S. B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res., 58, 3620-3626 (1998).
30. Minagawa, Y., Kigawa, J., Ishihara, H., Itamochi, H. and Terakawa, N. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn. J. Cancer Res., 85, 966-971 (1994).
31. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63 (1983).
32. Miller, S. A., Dykes. D. D. and Polesky, H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res., 16, 1215 (1988).
33. Wei, Q., Xu, X., Cheng, L., Legerski, R. J. and Ali-Osman, F. Simultaneous amplification of four DNA repair genes and β;-actin in human lymphocytes by multiplex reverse transcriptase-PCR. Cancer Res., 55, 5025-5029 (1995).
34. Fajac, A., Da Silva, J., Ahomadegbe, J. C., Rateau, J. G., Bernaudin, J. F., Riou, G. and Bernard, J. Cisplatin-induced apoptosis and p53 gene status in a cisplatin resistant human ovarian carcinoma cell line. Int. J. Cancer, 68, 67-74 (1996).
35. Segal-Bendirdjian, E. and Jacquemin-Sablon, A. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp. Cell Res., 218, 201-212 (1995).
36. Canitrot, Y., Frit, P. and Salles, B. Deficient apoptotic process in cisplatin-resistant L1210 cells cannot account for the cellular response to various drug treatments. Biochem. Biophy. Res. Commun., 234, 573-577 (1997).
37. Eichholtz-Wirth, H., Stoetzer, O. and Marx, K. Reduced expression of the ICE-related protease CPP32 is associated with radiation-induced cisplatin resistance in HeLa cells. Br. J. Cancer, 76, 1322-1327 (1997).
38. Song, K., Li, Z., Seth, P., Cowan, K. H. and Sinha, B. K. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Oncol. Res., 9, 603-609 (1997).
39. Perego, P., Romanelli, S., Carenini, N., Magnani, I., Leone, R., Bonetti, A., Paolicchi, A. and Zunino, F. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann. Oncol., 9, 423-430 (1998).